On April 10, 2019, senior representatives from China Pharmaceutical Innovation and Research Development Association (PhIRDA) met with experts from Drug Discovery Alliances Expert Working Group (DA-EWG) of Asia Partnership Conference of Pharmaceutical Associations (APAC) and R&D Committee of Japan Pharmaceutical Manufacturers Association (JPMA) in Japan. Participants had an in-depth discussion on topics including deepening exchanges, building a communication platform for innovative pharmaceutical enterprises, and achieving Win-Win Cooperation among pharmaceutical industries in China and Japan.
Dr. Atsushi Hasuoka, Head of APAC DA-EWG pointed out that he attended the 2017 China BioMed Innovation and Investment Conference (2017 CBIIC), and could sense China's emphasis on life science and further cooperation between the two parties.
Ms. Feng Lan, Secretary-General of PhIRDAappreciated JPMA R&D experts’ participation in 2017 CBIIC. She mentioned thatit was thereforms and supportive policies for capital market by China’s drug regulatory agency that brought China’s prosperous pharmaceutical industry and made introduction on the state of China's biopharmaceutical industry, R&D capacity of innovative enterprises. She encouraged Japan's leading pharmaceutical companies, innovation-based R&D companies and business partners to participate in 2019 CBIIC , where they present their innovative achievements, seek more financing opportunities, and promote the innovation of pharmaceutical industry. Mr. Zhang Dan expressed his opinions on how to strengthen the industrial cooperation between China and Japan after joining ICH.